Votrient: first targeted oral therapy for advanced soft tissue sarcoma

Votrient (pazopanib) has been approved as a treatment option for advanced soft tissue sarcoma (STS).

Votrient is also licensed for advanced renal cell carcinoma, as first line treatment or following cytokine therapy.
Votrient is also licensed for advanced renal cell carcinoma, as first line treatment or following cytokine therapy.

The tyrosine kinase inhibitor is indicated to treat selected subtypes of the disease in adults who have received prior chemotherapy for metastatic disease or who have progressed within 12 months of neo-adjuvant therapy.

Votrient is already licensed for the first-line treatment of adults with renal cell carcinoma (RCC) and for RCC patients who have received prior cytokine therapy for advanced disease.

Increased survival

The efficacy and safety of pazopanib in STS were assessed in a randomised, double-blind, placebo controlled, multicentre, phase III study (PALETTE) involving 369 patients with certain subtypes of advanced STS who had previously received chemotherapy.

Pazopanib 800mg once daily significantly increased median progression-free survival to 4.6 months, compared with 1.6 months for placebo (HR=0.31 [95% CI: 0.24–-0.40]; p<0.0001).

Adverse events identified in this advanced STS population that had not previously been seen in advanced RCC patients included venous thromboembolic events and pneumothorax.

View Votrient drug record

Further information: GSK

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in